Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★
Ran Reshef(Abramson Cancer Center), Daniel Tsai(University of Pennsylvania), Daniel F. Heitjan(Abramson Cancer Center), Edward A. Stadtmauer(University of Pennsylvania), Denis Hadjiliadis(University of Pennsylvania), Lee R. Goldberg(University of Pennsylvania), Karen Krok(University of Pennsylvania), Saran Vardhanabhuti, Simin Göral(University of Pennsylvania), David Porter(Texas Oncology), Marlise R. Luskin(Harvard University)
Cited by 218
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441